Lawrence Blatt
Chief Executive Officer chez ALIGOS THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Lawrence M.
Blatt was the founder of Alios BioPharma, Inc. (founded in 2008) where he held the title of President, Chief Executive Officer & Director from 2009 to 2014.
He was also the founder of Alveo Technologies, Inc. (founded in 2014) where he served as Chairman.
In addition, Dr. Blatt is the founder of Aligos Therapeutics, Inc. (founded in 2018) and currently holds the title of Chairman & Chief Executive Officer.
Dr. Blatt's current job(s) include being a Director at Global Virus Network and a Non-Executive Director at ReViral Ltd.Dr. Blatt's former job(s) include being Chairman at Meissa Vaccines, Inc., Global Head-Infectious Diseases & Vaccines at Johnson & Johnson from 2014 to 2018, Vice President-Research at Sirna Therapeutics, Inc. from 1998 to 2002, Chief Scientific Officer at InterMune, Inc. from 2002 to 2008, and Vice President-Product Development at National Genetics Institute, Inc. from 1996 to 1998.
Dr. Blatt's education history includes an MBA from California State University-Northridge, an undergraduate degree from Indiana University, and a doctorate from the University of La Verne.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/03/2024 | 2 120 633 ( 2,92% ) | 2 M $ | 31/03/2024 |
Postes actifs de Lawrence Blatt
| Sociétés | Poste | Début |
|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Chief Executive Officer | 05/02/2018 |
Global Virus Network
 Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Director/Board Member | - |
ReViral Ltd.
 ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | - |
Anciens postes connus de Lawrence Blatt
| Sociétés | Poste | Fin |
|---|---|---|
| JOHNSON & JOHNSON | Corporate Officer/Principal | 01/02/2018 |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Founder | 01/11/2014 |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | 01/01/2008 |
Sirna Therapeutics, Inc.
 Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/05/2002 |
National Genetics Institute, Inc.
 National Genetics Institute, Inc. Chemicals: SpecialtyProcess Industries Part of Laboratory Corp. of America Holdings, National Genetics Institute, Inc. provides hepatitis C testing and other laboratory services. The private company is based in Los Angeles, CA. The company was founded by Andrew J. Conrad, Michael A. Aicher. National Genetics Institute was acquired by Laboratory Corp. of America Holdings on August 01, 2000. | Corporate Officer/Principal | 01/01/1998 |
Formation de Lawrence Blatt
| California State University-Northridge | Masters Business Admin |
| Indiana University | Undergraduate Degree |
| University of La Verne | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Sirna Therapeutics, Inc.
Sirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Sirna Therapeutics, Inc. creates potent and stable siRNA compounds that are delivered into human cells resulting in the silencing of genes and viruses responsible for human diseases. The firm creates RNAi- based therapies to treat patients. The company was founded in 1992 and is headquartered in San Francisco, CA. | Commercial Services |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
National Genetics Institute, Inc.
National Genetics Institute, Inc. Chemicals: SpecialtyProcess Industries Part of Laboratory Corp. of America Holdings, National Genetics Institute, Inc. provides hepatitis C testing and other laboratory services. The private company is based in Los Angeles, CA. The company was founded by Andrew J. Conrad, Michael A. Aicher. National Genetics Institute was acquired by Laboratory Corp. of America Holdings on August 01, 2000. | Process Industries |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Commercial Services |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Alveo Technologies, Inc.
 Alveo Technologies, Inc. Medical SpecialtiesHealth Technology Alveo Technologies, Inc. operates a pre-clinical stage medical diagnostics company that creates infectious disease diagnostic devices. The company was founded by Ron Chiarello, Michael A. Aicher, Lawrence M. Blatt and Sumita Pennathur in 2014 and is headquartered in Alameda, CA. | Health Technology |
Meissa Vaccines, Inc.
 Meissa Vaccines, Inc. BiotechnologyHealth Technology Meissa Vaccines, Inc. operates as a pharmaceutical development company. It focuses on the in-licensing and advancement of vaccines for respiratory syncytial virus. The company was founded by Marty Moore and Roderick Tang in 2014 and is headquartered in South San Francisco, CA. | Health Technology |
